China Publishes Biotech 2026–2030 Plan while Global Biologics Hit 57% by 2030

China has published a new five-year proposal on what it considers to be progress in the biotech world. It’s quite an interesting take on how the country perceives development, because it mixes human capital, science and technology self-reliance, sustainability, rural revitalization, and social welfare, all this by using an advanced industry build-out.

I noticed the focus on the sustainability side of things and the creation of what it calls future industries, which includes biotech, advanced materials, and digital intelligence. All this will be linked with green transition to quality-of-life outcomes in education, health, public services. Note that it also ties agriculture and rural development to higher-value bio-based production, from biopharma to biomanufacturing, as part of advanced production, leaving behind low-margin extraction.

The document mirrors what many of us in the field already feel on the ground, and that is that policy is shifting from raw scale to value-density. That includes human health impact, verifiable sustainability, and resilient industrial capacity that can deliver complex bio-ingredients and materials at quality and cost.

Keep in mind that this is a political document. Nevertheless it holds some interesting elements that shouldn’t be overlooked by the West, a view shared by industrial biotechnology scientist Can KAYACILAR in her LinkedIn post yesterday.

Biotech is becoming a core economic infrastructure

To understand why biotech is getting a more important place in China’s policy, it is important to know that biotech is worldwide a key element in the economic motor. Here’s why:

• Medicine spending keeps climbing. IQVIA projects global medicine outlays to reach about $2.3 trillion by 2028, with usage rising to 3.8 trillion defined daily doses. That’s clearly a pipeline and manufacturing story.
• Biologics keep gaining share. Evaluate’s World Preview 2024 shows biologics overtaking small molecules in value, heading toward ~57% of prescription sales by 2030. That is a demand signal for bioprocess capacity and advanced modalities.
• Obesity medicines change markets. Analysts now peg anti-obesity drug sales near $150 billion annually by the early 2030s; IQVIA sees $131 billion by 2028. These numbers ripple through peptides, fill-finish, cold-chain, and payer policy.
• Regulators are still approving at pace. In 2024, EMA recommended 114 medicines (including 46 new active substances). The FDA (CDER) from its side cleared 50 novel drugs with high rates of priority and breakthrough designations. All this is a clear evidence of steady innovation throughput.

Worldwide we also notice important policy tailwinds:

• European Union: the Commission’s 2024 communication “Boosting Biotechnology and Biomanufacturing” frames biotech as a competitiveness and Green Deal lever, even floating a study toward a possible EU Biotech Act.
• United States: the White House launched the National Bioeconomy Board in March 2024 and outlined multi-agency Bold Goals spanning health, climate, agri-food, and supply-chain resilience.
• Global bioeconomy scale: the World Economic Forum and independent analyses value today’s bioeconomy around $4–5 trillion, with 50+ national strategies now in play.

Biomanufacturing: capacity, technologies, and the cost curve

The demand for biotech products only matters if you can make a good quality product at a profitable price of course. Let’s see how the global industry has adapted it’s process towards this goal.

• Capacity growth: Mammalian biomanufacturing capacity has expanded rapidly; industry sources track a path to ~8.9 million liters by 2028, with large greenfield investments and CDMO scale-ups.
• Single-use systems: Adoption of single-use bioreactors and assemblies has plateaued at a high levelwith a 87% usage in 2024. Facilities mix stainless, hybrid, and single-use for flexibility and cost control.
• Who’s adding steel? Announced projects (e.g., U.S. large-scale cell culture with multiple 20,000 L trains coming online by 2028) show the shift back to very-large stainless capacity for commercial biologics alongside modular single-use for clinical and niche runs.

EY’s Firepower 2025 calls 2024 a reset. The M&A value fell 41% to roughly $130 billion now that buyers targeted earlier-stage assets, but the volumes held up. It shows that partnerships, platform validation, and time-to-clinical data matter more than ever for financing.

Europe’s financing gap vs. its biotech ambitions

When it comes to Europe, we see that it has the policy. But it still needs the money. The EIB’s 2025 sector report estimates an annual €121.8 billion investment gap in the EU bio-economy – and $777 billion globally – if we want bio-based industry to meet climate, food, and health targets. As a result one may expect blended finance and first-of-a-kind (FOAK) de-risking to move to practice.

China’s biotech roadmap

The proposal’s biotechnology language doesn’t isolate biopharma and explicitly couples biomaterials, bioproduction, and agriculture-biotech with human health and environmental outcomes. That mix favors upcycling biotechnology, high-value bio-ingredients, and biolocalization. Shorter, smarter supply chains should create regional resilience and higher margins.

The plan holds 5 critical points:

1) Biotech becomes production power: Biomanufacturing sits in the same future-industry basket as quantum and 6G. Expect incentives for platform organisms, cell-free systems, precision fermentation, and enzymatic cascades that translate into advanced production with pilot plants and mid-scale validation baked into policy.

2) Upcycling biotech fits the circular economy playbook: The text talks about solid-waste governance, greener industry, and circularity open room for waste-to-value bioprocesses. That’s the theory, in practice lignocellulosic streams into bio-acids or PHA, food by-products into bioactive ingredients, and textile or plastic residues into monomers and waxes. And this especially inside industrial parks targeting zero-carbon status.

3) High value-added bioingredients sit where consumption meets health: The domestic-demand push and quality-upgrade in consumer goods plus health system modernization create pull for functional bioactives, precision nutrition, microbiome-derived compounds, and clean-label bio-based additives. All this with IP protection and government procurement favoring local innovation.

4) Biolocalization will matter: The policies emphasize supply-chain security, domestic platforms, and regional innovation hubs. That’s a true tailwind for localized strains, locally sourced feedstocks, and region-specific fermentation tuned to available biomass. It also aligns with county-level rural industry plans that integrate farming, processing, and services.

5) AI is now a core biotech toolchain: With “AI+” as a national action, expect compute and rules to support protein design, strain optimization, adaptive control, and QC automation under a governance framework you can actually plan against.

Three plays align with both the plan and global demand:

1. From basic research to advanced production: An IP should be built that scales with design-for-manufacture, validated quality attributes, and a line-of-sight to cGMP. Grant-funded discovery should be tied to CDMO-ready processes early (DoE, PAT, QC automation). The plan’s stress on systematic transformation matches how boards now evaluate biotech, as a bench-to-plant coherence.
2. Future-industry adjacency: Infrastructure for digital-bio economies with traceable and low-emission bioproducts will unlock compliance and cost in pharma, nutrition, and materials. EU policy and FDA/EMA throughput show markets are ready for category leaders that can ship at scale.
3. Planetary outcomes, measured: We can expect verified sustainability to be baked into unit economics (energy intensity, solvent recovery, water reuse, feedstock provenance). That’s nothing less than pure bankability, because public funds taper and private capital scrutinize pathway-to-profit and impact. The EIB numbers make this unavoidable.

From a sustainability-and-education vantage point, we at WINSS have long argued for proven benefit in technology adoption with school-to-industry pipelines that elevate human capital. The plan’s people-centered language and the EU/US policy stack both move in that direction: build talent, verify impact, publish the data, and steer capital to solutions that reduce waste, cut fossil inputs, and improve health.

What the plan proposes will only work if the following elements are considered in the execution. At the same time, it should be a clear sign to the EU and the US to upscale as well.

• Design for value, don’t focus first on volume: Tie every R&D sprint to a costed, qualifiable manufacturing step.
• Ride the policy rails: Map your tech to EU/US funding calls and national bio-economy priorities; the plan and Western policy both reward health impact, low-carbon production, and rural/industrial revitalization.
• Own your metrics: Publish energy, water, and carbon intensities and show progress over time; that unlocks concessional capital and lowers diligence friction with strategics.
• Think adjacency: Obesity, immunology, and oncology demand will keep pushing capacity and CDMO slots tight. This means that formulations, novel delivery, feedstock innovations, and QC automation are high-value insert points.
• Talent is policy.: The plan’s education-tech-investment triangle aligns perfectly with what schools and regions need: apprenticeships, GMP micro-credentials, and hands-on lab programs that translate directly to plant floors. Those partnerships should be built early.

Development over raw growth, but the EU and US need to move faster

China’s 2026–2030 proposal reads like a manifesto for development over raw growth. And instead of just looking at the sector in a lab centered way, it treats biotechnology as a civic and industrial tool.

That stance isn’t spectacular as such, after all it mirrors the global turn where regulators are clearing novel therapies, where demand is climbing, where capacity is expanding, and where public policy is swinging hard behind bio-based production.

The work displayed now is most of all operational. With this I mean that it wants to convert research into advanced production, verify sustainability, and scale where value compounds the fastest.

The EU and US from their side need to accelerate from policy to plants and do more than just publish strategies. The EU and the US must shift from pure strategy to execution. The vision is in place, but the deployment still lags. Align public money, permits, metrics, and procurement so policy turns into steel-in-the-ground capacity and audited outcomes.

A common scoreboard comes first. They should use a joint bio-KPI set for every publicly backed plant: kgCO₂e per kilogram produced, kWh per kilogram, water per batch, solvent-recovery percentage, feedstock provenance, and batch-pass rate.

Both should close the first-of-a-kind financing gap and pair capital with real infrastructure. At the same time, both should cut build friction. Impose for instance 180-day statutory clocks for permits on bio-industrial parks and grid connections, with parallel reviews to keep schedules intact.

While migration remains a hot topic, both should ideally move talent at the speed of construction so to speak. To achieve this, it’s key to fast-track visas and micro-credentials for bioprocess engineers, QC analysts, fermentation specialists, and AI-in-QC roles across borders.

Taken together, these and other steps convert high-level strategies in Brussels and Washington into plants that run, products that ship, and outcomes that can be measured.

---

---